Which drugs are commonly associated with hepatotoxicity?

Common Hepatotoxic Drugs

The most commonly implicated hepatotoxic drugs include antibiotics (particularly amoxicillin-clavulanate, nitrofurantoin, and minocycline), NSAIDs (especially diclofenac), statins (most commonly atorvastatin), anti-TNF agents (infliximab and adalimumab), antituberculosis medications (isoniazid, rifampin, and pyrazinamide), antiretrovirals (nevirapine and protease inhibitors), acetaminophen, and certain tyrosine kinase inhibitors.

Antibiotics: The Leading Class

Antibiotics represent the most frequently implicated drug class in hepatotoxicity cases 1, 2:

• Amoxicillin-clavulanate is the single most common cause of drug-induced liver injury (DILI) in prospective cohorts, accounting for 12.8-14% of all DILI cases 3, 4

  • Incidence: approximately 1 in 2,300 users 3
  • Clinical pattern varies by age: hepatocellular injury predominates in younger patients, cholestatic/mixed patterns in older patients 4
  • Most frequent cause of hospitalization for DILI 4

• Nitrofurantoin and minocycline are well-established causes of drug-induced autoimmune-like hepatitis (DI-AILH) 1, 2

  • Associated with autoantibodies in 40-80% of cases 1
  • Can present with interface hepatitis on biopsy 1

NSAIDs: Diclofenac Leads the Pack

NSAIDs account for approximately 10% of drug-induced hepatitis cases 5:

• Diclofenac is the most frequently implicated NSAID, representing 16 of 30 NSAID-related DILI cases in the U.S. DILI Network 6

  • Predominantly causes hepatocellular injury (70% of cases) 6
  • Also implicated in DI-AILH 1, 2
  • Should be reserved only for patients who fail other NSAIDs given safer alternatives 6

• General NSAID considerations: All NSAIDs carry hepatotoxic risk and should be avoided in patients with cirrhosis due to risks of nephrotoxicity, gastric bleeding, and decompensation 5

Cardiovascular Medications

Statins (particularly atorvastatin) are implicated in DI-AILH 1, 2:

• Unique pattern: May relapse spontaneously in 7 of 24 cases after steroid withdrawal, suggesting possible precipitation of idiopathic AIH rather than pure drug effect 1
• Despite reports, actual frequency of hepatotoxicity is lower than background population rates 7

Antihypertensives: Methyldopa and hydralazine are classic causes of DI-AILH 1, 2

Antituberculosis Medications: High-Risk Combinations

The rifampin-pyrazinamide (RZ) combination carries particularly severe hepatotoxicity risk 8:

• Hospitalization rate: 3.0 per 1,000 treatment initiations 8
• Death rate: 0.9 per 1,000 treatment initiations 8
• Should generally NOT be offered for latent TB treatment 8
• Pyrazinamide may be the most hepatotoxic first-line TB agent 8

Isoniazid (INH) causes hepatotoxicity with lower rates than previously thought:

• Modern studies show hospitalization rates of 0.1-0.2 per 1,000 and mortality rates of 0-0.3 per 1,000 8
• Improvement reflects careful patient selection and active monitoring 8

Antiretroviral Agents

Nevirapine has the greatest hepatotoxicity potential among NNRTIs 9:

• Incidence of hepatotoxicity: 12.5%, with clinical hepatitis in 1.1% 9
• Grade 4 liver enzyme elevation: 9.4% in African trials 9
• Two-thirds of cases occur within first 12 weeks 9
• Can present as hypersensitivity syndrome with rash, fever, eosinophilia 9
• Fulminant hepatic necrosis and death reported 9

Protease inhibitors (particularly ritonavir and ritonavir/saquinavir combinations) cause hepatotoxicity at any time during treatment 9:

• Hepatitis C coinfection is a major risk factor 9

Immunomodulatory Agents

Anti-TNF agents (infliximab > adalimumab) are well-established causes of DI-AILH 1, 2, 10:

• Highest risk among biologics: azathioprine and infliximab had highest DILI risk in prospective studies 3
• Can switch to different drug within same class after resolution without relapse 1
• Re-exposure to initially implicated drug is hazardous and rarely justified 1

Checkpoint inhibitors are increasingly recognized as hepatotoxic, now representing the most frequent cause of DILI in some recent cohorts 11

Analgesics

Acetaminophen causes dose-dependent hepatotoxicity:

• Doses <4g daily very unlikely to cause clinically significant hepatotoxicity 5
• Recommended dose in cirrhosis: 2-3g daily due to prolonged half-life 5
• Fulminant hepatic failure possible at therapeutic doses in chronic alcohol users 5

Other Notable Agents

• Interferons: Implicated in DI-AILH 1, 2
• Imatinib and other tyrosine kinase inhibitors: Associated with DI-AILH and reactive metabolite formation 1, 12, 1, 2
• Methylprednisolone: Paradoxically can cause DI-AILH 1
• Herbal/dietary supplements: Khat and Tinospora cordifolia implicated in DI-AILH 1, 2

Critical Clinical Pitfalls

1. Never re-expose patients to drugs that caused severe hepatotoxicity when alternatives exist 1

2. Avoid concurrent hepatotoxic medications in patients taking known hepatotoxins, including over-the-counter acetaminophen 8

3. Monitor high-risk patients closely: Those with hepatitis B/C coinfection, baseline elevated liver enzymes, alcohol use, or underlying liver disease 9, 8

4. Distinguish DI-AILH from idiopathic AIH: DI-AILH typically resolves after drug withdrawal with or without short-course corticosteroids and rarely relapses, unlike true AIH 1, 2

5. Age matters for NSAID hepatotoxicity pattern: Younger patients develop hepatocellular injury while older patients develop cholestatic patterns 4